ABC | Volume 114, Nº4, Abril 2020

Artigo Original Albuquerque et al. Polimorfismo Ser49Gly na insuficiência cardíaca Arq Bras Cardiol. 2020; 114(4):616-624 1. Brasil. Ministerio da Saude. [Internet]. DATASUS. Informaçes de saude, epidemiologicas emortalidade [acesso13mar. 2019 ]. Disponivel em: http:// datasus.saude.gov.br . 2. Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, et al. Early adoption of sacubitril/valsartan for patients with heart failure with reducedejection fraction: insights fromgetwiththeGuidelines-HeartFailure (GWTG-HF). JACC Heart Fail. 2017;5(4):305-9. 3. Small KM, Wagoner LE, Levin AM, Kardia S, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002;347(15):1135-42. 4. Abuzaanona A, Lanfear D. Pharmacogenomics of the natriuretic peptide system in heart failure. Curr Hear Fail Rep. 2017;14(6):536-42. 5. Albuquerque FN, Brandão AA, Silva DA, Mourilhe-Rocha R, Duque GS, Gondar AF, et al. Angiotensin-converting enzyme genetic polymorphism: its impact on cardiac remodeling. Arq Bras Cardiol. 2014;102(1):70-9. 6. Luzum JA, English JD, Ahmad US, Sun JW, Canan BD, Sadee W, et al. Association of genetic polymorphisms in the beta-1 adrenergic receptor with recovery of left ventricular ejection fraction in patients with heart failure. J Cardiovasc Transl Res. 2019;12(4):280-9. 7. BorjessonM,MagnussonY,HjalmarsonA,AnderssonB.Anovelpolymorphism inthegenecodingforthebeta(1)-adrenergicreceptorassociatedwithsurvival in patients with heart failure. Eur Heart J. 2000;21(22):1853-8. 8. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y. The myocardium-protective Gly-49 variant of the β 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down- regulation. J Biol Chem. 2002;277(34):30429-35. 9. Liu WN, Fu KL, Gao HY, Shang YY, Wang ZH, Jiang GH, et al. β 1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β -blocker therapy and prognosis. Plos One. 2012;7(7):e37659. 10. Biolo A, Clausell N, Santos KG, Salvaro R, Ashton-Prolla P, Borges A, et al. Impact of β 1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol. 2008;102(6):726-32. 11. Mialet-Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003;9(10):1300-5. 12. Lanfear DE, Peterson EL, Zeld N, Wells K, Sabbah HN, Williams K. Beta blocker survival benefit in heart failure is associated with ADRB1 Ser49Gly genotype. J Card Fail. 2015;21(8):S50. 13. Wang L, Lu L, Zhang F, ChenQ, ShenW. Polymorphisms of β -adrenoceptor and natriuretic peptide receptor genes influence the susceptibility to and the severity of idiopathic dilated cardiomyopathy in a Chinese cohort. J Card Fail. 2010;16(1):36-44. 14. Fiuzat M, Neely ML, Starr AZ, Kraus WE, Felker MG, Donahue M, et al. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTIONDNA substudy. Eur J Heart Fail. 2013;15(3):258-66. 15. LiggettSB,Mialet-Perez J,Thaneemit-ChenS,WeberSA,GreeneSM,Hodne D, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc National Acad Sci USA. 2006;103(30):11288-93. 16. Pereira SB, VellosoMW, Chermont S, QuintãoMM, Nunes Abdhala R, Giro C, et al. β -adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity. Mol Med Rep. 2013;7(1):259-65. 17. Magnusson Y, LevinMC, Eggertsen R, Nyström E, Mobini R, Schaufelberger M, et al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther. 2005;78(3):221-31. 18. Mangini S, Silveira F, Silva C, Grativvol P, da Seguro L, Ferreira S, et al. Decompensated heart failure in the emergency department of acardiology hospital. Arq Bras Cardiol. 2008;90(6):400-6. 19. Maqbool A, Hall AS, Ball SG, Balmforth AJ. Common polymorphisms of β 1-adrenoceptor: identification and rapid screening assay. Lancet.1999;353(9156):897. 20. SalantiG,AmountzaG,NtzaniEE, Ioannidis JP.Hardy–Weinbergequilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J HumGenet. 2005;13(7):840-8. 21. Raphael C, Briscoe C, Davies J, Ian Whinnett Z, Manisty C, Sutton R, et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart. 2007;93(4):476-82. 22. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34(19):1404-13. Referências Albuquerque FN, Brandão AA, Bittencourt MI; Revisão crítica do manuscrito quanto ao conteúdo intelectual importante: Albuquerque FN, Brandão AA, Bittencourt MI, Sales ALF, Spineti PPM, Duque GS, Albuquerque D. Potencial conflito de interesses Declaro não haver conflito de interesses pertinentes. Fontes de financiamento O presente estudo foi financiado por FAPERJ (Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro). Vinculação acadêmica Este artigo é parte de tese de Doutorado de Felipe neves de Albuquerque pelo Programa de Pós-Graduação em Ciências Médicas da Faculdade de Ciências Médicas da Universidade do Estado do Rio de Janeiro (FCM-UERJ). Aprovação ética e consentimento informado Este estudo foi aprovado pelo Comitê de Ética do Hospital Universitário Pedro Ernesto sob o número de protocolo CAAE: 0176.0.228-000-09. Todos os procedimentos envolvidos nesse estudo estão de acordo com a Declaração de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes incluídos no estudo. 623